Revance Therapeutics (RVNC) Tops Q3 EPS by 25c

November 3, 2016 5:00 PM EDT
Get Alerts RVNC Hot Sheet
Trade RVNC Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.64), $0.25 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment